XINTELA GRANTED 2 MILLION SEK FROM VINNOVA Lund, Sweden, March 27, 2020 - Xintela has been granted 2 million SEK from Vinnova in the call for "Innovation projects in small and medium-sized companies". The grant concerns one of the companys cancer projects and the work to develop targeted therapies for aggressive cancers with integrin 10-binding ADCs. "This is very good news for Xintelas cancer research. Our cancer project was granted the maximum amount in competition with a large number of applications, which is a great quality stamp for the project", says Xintelas CEO Evy Lundgren-Åkerlund. Xintela has previously reported that an "Antibody-Drug Conjugate" (ADC), in which a toxin is linked to an integrin 101-binding antibody, has a targeting and cell-killing effect on glioblastoma cells both in cell studies and in an animal model. The results have been published in the journal Cancers (2019, 11, 587). Xintela has now applied for and been granted co-financing from Vinnova to preclinically evaluate various ADCs to identify an optimal ADC-candidate for the treatment of brain tumor glioblastoma and other aggressive cancers. Xintela has patent applications covering the use of integrin 10 antibodies for the treatment of tumors in the CNS and other aggressive tumors. Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 Email: evy@xintela.se mailto:evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se http://www.xintela.se The following documents can be retrieved from beQuoted 2020-03-27-Xintela-tilldelas-2-miljoner ENG.pdf-http://www.bequoted.com/beQPress/download.asp?Id=28609 About Xintela Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK(r). The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintelas Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se mailto:certifiedadviser@penser.se .